» Articles » PMID: 32887496

Biomarkers of Exposure Among USA Adult Hookah Users: Results from Wave 1 of the Population Assessment of Tobacco and Health (PATH) Study (2013-2014)

Abstract

Hookah smoking has become common in the USA, especially among young adults. This study measured biomarkers of exposure to known tobacco product toxicants in a population-based sample of exclusive, established hookah users. Urinary biomarker data from 1753 adults in Wave 1 of the Population Assessment of Tobacco and Health (PATH) Study were used to compare geometric mean concentrations of biomarkers of exposure in exclusive, established past 30-day hookah users to never users of tobacco. Geometric mean ratios were calculated comparing hookah user groups with never users adjusting for age, sex, race/ethnicity, education, past 30-day marijuana use, secondhand smoke exposure and creatinine. Past 30-day hookah users ( = 98) had 10.6 times the urinary cotinine level of never tobacco users. Compared to never tobacco users, past 30-day hookah users had 2.3 times the level of the carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), a metabolite of the tobacco-specific nitrosamine (TSNA) 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), 1.3 times higher polycyclic aromatic hydrocarbons (PAHs) 3-hydroxyfluorene and 1-hydroxypyrene, 1.8 times higher levels of acrylonitrile, 1.3 times higher levels of acrylamide, and 1.2 times higher levels of acrolein exposure. These data indicate that hookah use is a significant source of exposure to nicotine, carcinogens, and respiratory toxicants.

Citing Articles

Associations between biomarkers of nicotine/tobacco exposure and respiratory symptoms among adults who exclusively smoke cigarettes in the U.S.: Findings from the PATH Study Waves 1-4 (2013-2017).

Edwards K, Ozga J, Reyes-Guzman C, Smith D, Hatsukami D, Hart J Addict Behav Rep. 2023; 17:100487.

PMID: 37008740 PMC: 10060600. DOI: 10.1016/j.abrep.2023.100487.


Prevalence of hookah smoking among Iranian pupils and university students: An updated systematic review and meta-analysis.

Zaheri H, Raziani Y, Khademi N, Moradi Y, Shahriari H, Ghanei-Gheshlagh R Clin Respir J. 2022; 16(6):425-440.

PMID: 35665461 PMC: 9366573. DOI: 10.1111/crj.13511.


1,3-Butadiene: a ubiquitous environmental mutagen and its associations with diseases.

Chen W, Zhang X Genes Environ. 2022; 44(1):3.

PMID: 35012685 PMC: 8744311. DOI: 10.1186/s41021-021-00233-y.


Associations of Smokeless Tobacco Use With Cardiovascular Disease Risk: Insights From the Population Assessment of Tobacco and Health Study.

Rezk-Hanna M, Warda U, Stokes A, Fetterman J, Li J, Macey P Nicotine Tob Res. 2022; 24(7):1063-1070.

PMID: 34999825 PMC: 9199939. DOI: 10.1093/ntr/ntab258.


Development and Pretesting of Hookah Tobacco Public Education Messages for Young Adults.

Phan L, Villanti A, Leshner G, Wagener T, Stevens E, Johnson A Int J Environ Res Public Health. 2020; 17(23).

PMID: 33255675 PMC: 7728075. DOI: 10.3390/ijerph17238752.

References
1.
Xia B, Xia Y, Wong J, Nicodemus K, Xu M, Lee J . Quantitative analysis of five tobacco-specific N-nitrosamines in urine by liquid chromatography-atmospheric pressure ionization tandem mass spectrometry. Biomed Chromatogr. 2013; 28(3):375-84. DOI: 10.1002/bmc.3031. View

2.
Caudill S, Schleicher R, Pirkle J . Multi-rule quality control for the age-related eye disease study. Stat Med. 2008; 27(20):4094-106. DOI: 10.1002/sim.3222. View

3.
Primack B, Hopkins M, Hallett C, Carroll M, Zeller M, Dachille K . US health policy related to hookah tobacco smoking. Am J Public Health. 2012; 102(9):e47-51. PMC: 3482044. DOI: 10.2105/AJPH.2012.300838. View

4.
Pazo D, Moliere F, Sampson M, Reese C, Agnew-Heard K, Walters M . Mainstream Smoke Levels of Volatile Organic Compounds in 50 U.S. Domestic Cigarette Brands Smoked With the ISO and Canadian Intense Protocols. Nicotine Tob Res. 2016; 18(9):1886-94. PMC: 5687062. DOI: 10.1093/ntr/ntw118. View

5.
Chang C, Edwards S, Arab A, Del Valle-Pinero A, Yang L, Hatsukami D . Biomarkers of Tobacco Exposure: Summary of an FDA-Sponsored Public Workshop. Cancer Epidemiol Biomarkers Prev. 2017; 26(3):291-302. PMC: 5336443. DOI: 10.1158/1055-9965.EPI-16-0675. View